The Potential Role of m6A RNA Methylation in the Aging Process and Aging-Associated Diseases.

N6-methyladenosine (mA) is the most common and conserved internal eukaryotic mRNA modification. mA modification is a dynamic and reversible post-transcriptional regulatory modification, initiated by methylase and removed by RNA demethylase. mA-binding proteins recognise the mA modification to regulate gene expression. Recent studies have shown that altered mA levels and abnormal regulator expression are crucial in the ageing process and the occurrence of age-related diseases. In this review, we summarise some key findings in the field of mA modification in the ageing process and age-related diseases, including cell senescence, autophagy, inflammation, oxidative stress, DNA damage, tumours, neurodegenerative diseases, diabetes, and cardiovascular diseases (CVDs). We focused on the biological function and potential molecular mechanisms of mA RNA methylation in ageing and age-related disease progression. We believe that mA modification may provide a new target for anti-ageing therapies.